AngioDynamics Inc (ANGO)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $495.40M
Last updated: Nov 17, 2026 at 4:15 PM ET
AngioDynamics Inc (ANGO) Statistics
AngioDynamics (ANGO) has a market cap of $495.40M and an enterprise value of $461.43M. It kept -10.12% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 6.86% below the market cap, as cash exceeds debt.
| Market Cap | $495.40M |
|---|---|
| Enterprise Value | $461.43M |
| Latest price (Nov 17, 2026) | $11.49 |
Key Dates
The next earnings report is expected on Jan 4, 2027, covering the quarter ending Nov 30, 2026.
| Next Earnings Date | Jan 4, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 8, 2026 |
| Fiscal Year End | May |
Valuation Ratios
Sales and book value multiples are 1.5x and 2.9x. Its year-end P/S ranged from 0.9x to 3.5x from 2016 to 2025.
| P/S Ratio | 1.5x |
|---|---|
| Forward P/S | 1.5x |
| P/B Ratio | 2.9x |
| P/TBV Ratio | 4.7x |
| P/OCF Ratio | 134.9x |
Price Statistics
The stock is down 5.12% over 52 weeks and trades 13.48% below its 50-day average.
| Beta (1Y) | 1.05 |
|---|---|
| 52-Week Change | -5.12% |
| 1-Month Change | +0.88% |
| 3-Month Change | -28.50% |
| 6-Month Change | +0.44% |
| 5-Year Change | -58.08% |
| 10-Year Change | -24.78% |
| Total Return (1Y) | -5.12% |
| Total Return (3Y CAGR) | +18.99% |
| Total Return (5Y CAGR) | -16.83% |
| Return vs SPY (1Y) | -14.84% |
| Max Drawdown (1Y) | -32.42% |
| Max Drawdown (3Y) | -35.32% |
| Sharpe Ratio (1Y) | -0.07 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $13.28 |
| 200-Day Average | $12.57 |
| 52-Week Range | $9.39 to $16.29 |
| RSI (14 Days) | 38.7 |
| Average Volume (20 Days) | 528.57K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.40x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.40x |
|---|---|
| Quick Ratio | 1.48x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -20.09% over the last 12 months, against a 5-year average of -29.97%.
| Return on Equity (ROE) | -20.09% |
|---|---|
| Return on Assets (ROA) | -13.61% |
| Return on Capital Employed (ROCE) | -17.76% |
| ROE (5Y Average) | -29.97% |
| ROA (5Y Average) | -19.71% |
| ROIC (5Y Average) | -28.90% |
| Asset Turnover | 1.28x |
| Inventory Turnover | 2.69x |
| Receivables Turnover | 6.98x |
| Cash Conversion Cycle | 115 days |
Scores
ANGO has an Altman Z-Score of 2.29, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.29 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $325.38M over the last 12 months is up 8.20% from the 12 months before.
| Revenue | $325.38M |
|---|---|
| Revenue Growth (YoY) | +8.20% |
| Gross Profit | $181.07M |
| Operating Income | -$36.57M |
| Pretax Income | -$32.76M |
| Net Income | -$32.94M |
| EBITDA | -$9.94M |
| EBIT | -$32.38M |
| Reported EPS (TTM) | -$0.24 |
Trailing 12 months through Aug 31, 2026.
Balance Sheet
Shareholder equity funds 67.77% of the $241.93M in total assets.
| Cash and Equivalents | $33.97M |
|---|---|
| Total Debt | $0 |
| Net Cash | $33.97M |
| Net Cash Per Share | $0.81 |
| Working Capital | $83.31M |
| Shareholder Equity | $163.96M |
| Book Value Per Share | $3.90 |
| Tangible Book Value | $102.07M |
| Tangible Book Per Share | $2.43 |
| Total Assets | $241.93M |
| Total Liabilities | $77.97M |
Balance sheet as of Aug 31, 2026.
Cash Flow
After $8.37M of capital spending, operating cash flow left -$4.70M of free cash flow.
| Operating Cash Flow | $3.67M |
|---|---|
| Capital Expenditures | $8.37M |
| Free Cash Flow | -$4.70M |
| FCF Per Share | -$0.11 |
| Depreciation and Amortization | $22.43M |
Trailing 12 months through Aug 31, 2026.
Margins
The operating margin is -11.24%, against a 5-year average of -22.71%.
| Gross Margin | 55.65% |
|---|---|
| Operating Margin | -11.24% |
| Pretax Margin | -10.07% |
| Net Margin | -10.12% |
| EBITDA Margin | -3.06% |
| EBIT Margin | -9.95% |
| FCF Margin | -1.44% |
| Gross Margin (5Y Average) | 52.66% |
| Operating Margin (5Y Average) | -22.71% |
| Net Margin (5Y Average) | -21.53% |
Growth
Revenue fell 1.86% a year over 3 years.
| Revenue Growth (3Y CAGR) | -1.86% |
|---|---|
| Revenue Growth (5Y CAGR) | +1.93% |
| FCF Growth (5Y CAGR) | -51.49% |
Dividends and Yields
ANGO does not pay a dividend. Its free cash flow yield is -0.97%.
| FCF Yield | -0.97% |
|---|---|
| Buyback Yield | 0.12% |
| Shareholder Yield | 0.12% |
Peer Position
Against 11 similar companies, ANGO has the 10th highest P/S.
P/S RatioPeer median 3.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.29%
| P/S Ratio | 1.5x vs 3.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +8.20% vs +7.29% median |
Analyst Forecast
Consensus estimates put revenue growth at 5.28% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +5.28% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ANGO
What is ANGO's market cap?
AngioDynamics has a market cap of $495.40M. Its enterprise value, which adds debt and subtracts cash, is $461.43M.
How many shares of ANGO are outstanding?
AngioDynamics has 42.02M shares outstanding. The count is up 2.06% from a year earlier.
Does ANGO pay a dividend?
No. AngioDynamics does not pay a dividend.
How much debt does ANGO have?
AngioDynamics has $0 of total debt and $33.97M of cash and equivalents, a net cash position of $33.97M.
ANGO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts